BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17786337)

  • 1. Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma.
    Kudo S; Konda R; Obara W; Kudo D; Tani K; Nakamura Y; Fujioka T
    Oncol Rep; 2007 Oct; 18(4):785-91. PubMed ID: 17786337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of angiostatin cDNA in a murine renal cell carcinoma suppresses tumor growth in vivo.
    Fukumori T; Nishitani Ma; Naroda T; Onishi T; Oka N; Kanayama Ho; Kagawa S
    Urology; 2002 Jun; 59(6):973-7. PubMed ID: 12031397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic effect of ZD1839 against murine renal cell carcinoma (RENCA) in an orthotopic mouse model.
    Oh HY; Kwon SM; Kim SI; Jae YW; Hong SJ
    Urol Int; 2005; 75(2):159-66. PubMed ID: 16123571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain-specific angiogenesis inhibitor 1 is a putative factor for inhibition of neovascular formation in renal cell carcinoma.
    Izutsu T; Konda R; Sugimura J; Iwasaki K; Fujioka T
    J Urol; 2011 Jun; 185(6):2353-8. PubMed ID: 21511296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
    Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
    Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model.
    Verheul HM; Hammers H; van Erp K; Wei Y; Sanni T; Salumbides B; Qian DZ; Yancopoulos GD; Pili R
    Clin Cancer Res; 2007 Jul; 13(14):4201-8. PubMed ID: 17634549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.
    Medinger M; Esser N; Zirrgiebel U; Ryan A; Jürgensmeier JM; Drevs J
    Anticancer Res; 2009 Dec; 29(12):5065-76. PubMed ID: 20044618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.
    Drevs J; Konerding MA; Wolloscheck T; Wedge SR; Ryan AJ; Ogilvie DJ; Esser N
    Angiogenesis; 2004; 7(4):347-54. PubMed ID: 15886878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma.
    Morita T; Shinohara N; Tokue A
    Br J Urol; 1994 Oct; 74(4):416-21. PubMed ID: 7529632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid, in vivo, evaluation of antiangiogenic and antineoplastic gene products by nonviral transfection of tumor cells.
    Weiss JM; Shivakumar R; Feller S; Li LH; Hanson A; Fogler WE; Fratantoni JC; Liu LN
    Cancer Gene Ther; 2004 May; 11(5):346-53. PubMed ID: 15031722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
    Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
    Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.
    Hwang KS; Cho WK; Yoo J; Yun HJ; Kim S; Im DS
    BMC Cancer; 2005 May; 5():51. PubMed ID: 15910693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model.
    Yoon KC; Ahn KY; Lee JH; Chun BJ; Park SW; Seo MS; Park YG; Kim KK
    Gene Ther; 2005 Apr; 12(7):617-24. PubMed ID: 15703766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma.
    Fujioka T; Hasegawa M; Ishikura K; Matsushita Y; Sato M; Tanji S
    J Urol; 1998 Jul; 160(1):247-51. PubMed ID: 9628658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo.
    Nishimatsu H; Takeuchi T; Ueki T; Kajiwara T; Moriyama N; Ishida T; Li B; Kakizoe T; Kitamura T
    Cancer Immunol Immunother; 1999 Apr; 48(1):56-61. PubMed ID: 10235489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of angiogenesis inhibitor 0-(chloroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma.
    Fujioka T; Hasegawa M; Ogiu K; Matsushita Y; Sato M; Kubo T
    J Urol; 1996 May; 155(5):1775-8. PubMed ID: 8627882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene transfer of a soluble receptor of VEGF inhibits the growth of experimental eyelid malignant melanoma.
    Shiose S; Sakamoto T; Yoshikawa H; Hata Y; Kawano Y; Ishibashi T; Inomata H; Takayama K; Ueno H
    Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2395-403. PubMed ID: 10937546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
    Horiguchi A; Sumitomo M; Asakuma J; Asano T; Asano T; Hayakawa M
    Clin Cancer Res; 2004 Dec; 10(24):8648-55. PubMed ID: 15623649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.